IL134830A0 - Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them - Google Patents

Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them

Info

Publication number
IL134830A0
IL134830A0 IL13483000A IL13483000A IL134830A0 IL 134830 A0 IL134830 A0 IL 134830A0 IL 13483000 A IL13483000 A IL 13483000A IL 13483000 A IL13483000 A IL 13483000A IL 134830 A0 IL134830 A0 IL 134830A0
Authority
IL
Israel
Prior art keywords
peptides
immunostimulatory
pharmaceutical compositions
compositions containing
stimulating
Prior art date
Application number
IL13483000A
Other languages
English (en)
Original Assignee
Chay 13 Medical Res Group N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chay 13 Medical Res Group N V filed Critical Chay 13 Medical Res Group N V
Priority to IL13483000A priority Critical patent/IL134830A0/xx
Priority to HU0301003A priority patent/HUP0301003A3/hu
Priority to IL15135101A priority patent/IL151351A0/xx
Priority to DK01908105.8T priority patent/DK1261360T3/da
Priority to DE60140794T priority patent/DE60140794D1/de
Priority to AU35962/01A priority patent/AU782662B2/en
Priority to CZ20022915A priority patent/CZ20022915A3/cs
Priority to CA002401550A priority patent/CA2401550A1/en
Priority to EA200200820A priority patent/EA005579B1/ru
Priority to BR0109027-5A priority patent/BR0109027A/pt
Priority to PCT/IL2001/000198 priority patent/WO2001064234A1/en
Priority to NZ521016A priority patent/NZ521016A/en
Priority to PL36130701A priority patent/PL361307A1/xx
Priority to EA200401467A priority patent/EA007217B1/ru
Priority to MXPA02008569A priority patent/MXPA02008569A/es
Priority to JP2001563131A priority patent/JP2003528827A/ja
Priority to EP01908105A priority patent/EP1261360B1/en
Priority to CN01808959A priority patent/CN1427725A/zh
Priority to AT01908105T priority patent/ATE451929T1/de
Publication of IL134830A0 publication Critical patent/IL134830A0/xx
Priority to US09/942,121 priority patent/US20020147144A1/en
Priority to IL151351A priority patent/IL151351A/en
Priority to ZA200206842A priority patent/ZA200206842B/en
Priority to EA200400376A priority patent/EA007814B1/ru
Priority to NO20024157A priority patent/NO20024157L/no
Priority to KR10-2002-7011450A priority patent/KR20030025907A/ko
Priority to US10/788,400 priority patent/US7666996B2/en
Priority to US11/518,400 priority patent/US7741274B2/en
Priority to US11/982,369 priority patent/US20090192081A1/en
Priority to US12/764,996 priority patent/US20100298216A1/en
Priority to US12/844,834 priority patent/US20100317601A1/en
Priority to US13/603,428 priority patent/US8735348B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4732—Casein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
IL13483000A 2000-03-01 2000-03-01 Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them IL134830A0 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
IL13483000A IL134830A0 (en) 2000-03-01 2000-03-01 Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
DK01908105.8T DK1261360T3 (da) 2000-03-01 2001-03-01 Casein-afledte peptider og anvendelser deraf i behandling
CN01808959A CN1427725A (zh) 2000-03-01 2001-03-01 酪蛋白衍生肽及其治疗用途
JP2001563131A JP2003528827A (ja) 2000-03-01 2001-03-01 カゼイン由来ペプチドおよびその医療用途
DE60140794T DE60140794D1 (de) 2000-03-01 2001-03-01 Von casein abgeleitete peptide und deren anwendung für die therapie
AU35962/01A AU782662B2 (en) 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy
CZ20022915A CZ20022915A3 (cs) 2000-03-01 2001-03-01 Čištěný peptid a farmaceutický prostředek s jeho obsahem
CA002401550A CA2401550A1 (en) 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy
EA200200820A EA005579B1 (ru) 2000-03-01 2001-03-01 Пептиды, полученные из казеина, и их применение в терапии
BR0109027-5A BR0109027A (pt) 2000-03-01 2001-03-01 Peptìdios derivados de caseìna e usos dos mesmos em terapia
IL15135101A IL151351A0 (en) 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy
NZ521016A NZ521016A (en) 2000-03-01 2001-03-01 Alpha(s1) casein derived peptides from the N terminus portion and uses thereof in pharmaceutical compositions
PL36130701A PL361307A1 (en) 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy
EA200401467A EA007217B1 (ru) 2000-03-01 2001-03-01 Пептиды, полученные из казеина, и их применение в терапии
MXPA02008569A MXPA02008569A (es) 2000-03-01 2001-03-01 Peptidos derivados de caseina y usos de los mismos en terapia.
HU0301003A HUP0301003A3 (en) 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy
PCT/IL2001/000198 WO2001064234A1 (en) 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy
EP01908105A EP1261360B1 (en) 2000-03-01 2001-03-01 Casein derived peptides and uses thereof in therapy
AT01908105T ATE451929T1 (de) 2000-03-01 2001-03-01 Von casein abgeleitete peptide und deren anwendung für die therapie
US09/942,121 US20020147144A1 (en) 2000-03-01 2001-08-30 Casein derived peptides and uses thereof in therapy
IL151351A IL151351A (en) 2000-03-01 2002-08-19 Peptides derived from casein and their use in healing
ZA200206842A ZA200206842B (en) 2000-03-01 2002-08-27 Casein derived peptides and uses thereof in therapy.
EA200400376A EA007814B1 (ru) 2000-03-01 2002-08-29 Пептиды, полученные из казеина, и их использование в терапии
NO20024157A NO20024157L (no) 2000-03-01 2002-08-30 Kasein-avledete peptider og anvendelser derav i terapi
KR10-2002-7011450A KR20030025907A (ko) 2000-03-01 2002-08-31 카세인 유도 펩타이드 및 이들의 치료 용도
US10/788,400 US7666996B2 (en) 2000-03-01 2004-03-01 Casein derived peptides and uses thereof
US11/518,400 US7741274B2 (en) 2000-03-01 2006-09-08 Casein derived peptides and uses thereof in therapy
US11/982,369 US20090192081A1 (en) 2000-03-01 2007-10-31 Casein derived peptides and uses thereof
US12/764,996 US20100298216A1 (en) 2000-03-01 2010-04-22 Casein Derived Peptides And Uses Thereof in Therapy
US12/844,834 US20100317601A1 (en) 2000-03-01 2010-07-28 Casein Derived Peptides And Uses Thereof
US13/603,428 US8735348B2 (en) 2000-03-01 2012-09-05 Casein derived peptides and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13483000A IL134830A0 (en) 2000-03-01 2000-03-01 Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them

Publications (1)

Publication Number Publication Date
IL134830A0 true IL134830A0 (en) 2001-05-20

Family

ID=11073892

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13483000A IL134830A0 (en) 2000-03-01 2000-03-01 Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
IL151351A IL151351A (en) 2000-03-01 2002-08-19 Peptides derived from casein and their use in healing

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL151351A IL151351A (en) 2000-03-01 2002-08-19 Peptides derived from casein and their use in healing

Country Status (21)

Country Link
US (6) US20020147144A1 (xx)
EP (1) EP1261360B1 (xx)
JP (1) JP2003528827A (xx)
KR (1) KR20030025907A (xx)
CN (1) CN1427725A (xx)
AT (1) ATE451929T1 (xx)
AU (1) AU782662B2 (xx)
BR (1) BR0109027A (xx)
CA (1) CA2401550A1 (xx)
CZ (1) CZ20022915A3 (xx)
DE (1) DE60140794D1 (xx)
DK (1) DK1261360T3 (xx)
EA (3) EA005579B1 (xx)
HU (1) HUP0301003A3 (xx)
IL (2) IL134830A0 (xx)
MX (1) MXPA02008569A (xx)
NO (1) NO20024157L (xx)
NZ (1) NZ521016A (xx)
PL (1) PL361307A1 (xx)
WO (1) WO2001064234A1 (xx)
ZA (1) ZA200206842B (xx)

Families Citing this family (142)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0212625A (pt) * 2001-08-30 2007-06-19 Chay 13 Medical Res Group N V peptìdeos derivados de caseìna e usos dos mesmos em terapia
WO2003067904A2 (en) * 2002-02-06 2003-08-14 University Of North Carolina At Chapel Hill High-throughput cell identification and isolation method and apparatus
EP1359157A1 (en) * 2002-04-29 2003-11-05 Société des Produits Nestlé S.A. Metallo-proteinase inhibitory agent
KR101188292B1 (ko) * 2002-11-27 2012-10-09 디엠아이 바이오사이언시스, 인크 인산화 증가로 인한 질병 및 증상의 치료방법
GB0313892D0 (en) * 2003-06-16 2003-07-23 Hannah Res Inst Control of lactation
CA2558155A1 (en) * 2004-03-01 2005-09-09 Zvi Sidelman Casein derived peptides and therapeutic uses thereof
BRPI0509541A (pt) 2004-03-30 2007-09-18 Monsanto Technology Llc métodos para controlar agentes patógenos de planta utilizando n-fosfonometilglicina
WO2005099724A2 (en) * 2004-04-13 2005-10-27 Parallel Solutions, Inc. Functionalized water-soluble polyphosphazene and uses thereof as modifiers of biological agents
US9000040B2 (en) 2004-09-28 2015-04-07 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
EP1811935B1 (en) 2004-09-28 2016-03-30 Atrium Medical Corporation Heat cured gel and method of making
US9012506B2 (en) 2004-09-28 2015-04-21 Atrium Medical Corporation Cross-linked fatty acid-based biomaterials
GB0423352D0 (en) * 2004-10-21 2004-11-24 Hannah Res Inst "Control of mammary cell number"
AU2006242842B2 (en) * 2005-05-02 2011-12-08 Mileutis Ltd. Pharmaceutical compositions comprising casein derived peptides and methods of use thereof
ES2319475B1 (es) * 2005-06-08 2010-02-16 Consejo Superior Investig. Cientificas Peptidos bioactivos identificados en hidrolizados enzimaticos de caseinas lacteas y procedimiento de obtencion.
US11266607B2 (en) * 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US9278161B2 (en) 2005-09-28 2016-03-08 Atrium Medical Corporation Tissue-separating fatty acid adhesion barrier
US9427423B2 (en) 2009-03-10 2016-08-30 Atrium Medical Corporation Fatty-acid based particles
CN101351554B (zh) 2005-10-04 2016-05-18 索利金尼克斯公司 包括通过调节先天免疫治疗和预防感染在内的治疗和预防免疫相关疾病的新型肽
US20070086958A1 (en) * 2005-10-14 2007-04-19 Medafor, Incorporated Formation of medically useful gels comprising microporous particles and methods of use
GB2436328A (en) * 2006-03-22 2007-09-26 Regen Therapeutics Plc Peptide derived from colostrinin
WO2007110296A1 (en) * 2006-03-24 2007-10-04 Unilever N.V. Healthy food product
EP1836906B1 (en) * 2006-03-24 2009-07-01 Unilever N.V. Healthy food product
BRPI0717500A2 (pt) * 2006-10-04 2014-03-25 Inimex Pharmaceuticals Inc Peptídeos para o tratamento e a prevenção de desordens relacionadas à imunidade, incluindo tratamento e prevenção de infecção por modulação da imunidade inata.
JP5592652B2 (ja) * 2007-02-05 2014-09-17 ナショナル ユニバーシティ オブ シンガポール 推定サイトカイニン受容体およびその使用方法
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
US20110004019A1 (en) * 2008-03-12 2011-01-06 Shiseido Company Ltd. Parakeratosis Inhibitor, Pore-Shrinking Agent, Or Rough Skin Inhibiting/Ameliorating Agent, And External Composition For Skin Containing The Same
KR101355695B1 (ko) * 2009-02-06 2014-01-27 더 프록터 앤드 갬블 캄파니 붕괴성 수분-함유 캡슐
US20130195983A1 (en) * 2009-04-10 2013-08-01 Neil P. Desai Nanoparticle formulations and uses thereof
CN105476951A (zh) 2009-05-04 2016-04-13 普西维达公司 多孔硅药物洗脱颗粒
WO2010135324A1 (en) * 2009-05-18 2010-11-25 Monsanto Technology Llc Use of glyphosate for disease suppression and yield enhancement in soybean
GB0912481D0 (en) 2009-07-17 2009-08-26 Reckitt Benckiser Healthcare I Skincare compositions
US20110038910A1 (en) 2009-08-11 2011-02-17 Atrium Medical Corporation Anti-infective antimicrobial-containing biomaterials
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
BR112012015653B1 (pt) * 2009-12-29 2023-09-26 W.R. Grace & Co. -Conn. Composição que compreende um material de sílica particulado poroso e película transparente que compreende a mesma
AU2011212859B2 (en) * 2010-02-04 2014-05-08 Isp Investments Inc. Self adapting polymers for anhydrous sunscreen formulations
MX2012009634A (es) * 2010-02-18 2012-09-28 Athenix Corp Genes delta-endotoxinicos axmi218, axmi219, axmi220, axmi226, axmi227, axmi228, axmi229, axmi230, y axmi231 y metodos para sus uso.
AR080200A1 (es) * 2010-02-18 2012-03-21 Athenix Corp Genes delta-endotoxinicos axmi221z, axmi222z, axmi223z, axmi224z, y axmi225z y metodos para su uso
HUE033056T2 (hu) 2010-03-08 2017-11-28 Monsanto Technology Llc Polinukleotid molekulák génszabályozáshoz növényekben
FR2958155B1 (fr) * 2010-04-02 2012-04-20 Oreal Composition de decoloration comprenant un sel peroxygene dans une base fortement riche en corps gras
WO2011137563A1 (en) * 2010-05-07 2011-11-10 Unilever Plc High solvent content emulsions
JP5957447B2 (ja) 2010-06-04 2016-07-27 モンサント テクノロジー エルエルシー 遺伝子組換えアブラナ事象ｍｏｎ８８３０２および同使用方法
WO2012009707A2 (en) 2010-07-16 2012-01-19 Atrium Medical Corporation Composition and methods for altering the rate of hydrolysis of cured oil-based materials
CN103201388A (zh) * 2010-08-19 2013-07-10 先锋国际良种公司 对鳞翅目昆虫具有活性的新苏云金杆菌基因
US9757374B2 (en) 2010-10-28 2017-09-12 Aequus Pharmaceuticals Inc. Aripiprazole compositions and methods for its transdermal delivery
CA2816203C (en) * 2010-10-28 2017-02-21 Transdermal Research Pharm Laboratories, Llc Aripiprazole compositions and methods for its transdermal delivery
CN104622790A (zh) 2010-11-01 2015-05-20 普西维达公司 用于递送治疗剂的可生物侵蚀的硅基装置
US20120311734A1 (en) * 2011-06-04 2012-12-06 The Texas A&M University System Potato transformation compositions, systems, methods, microorganisms, and plants
AU2012296987A1 (en) * 2011-08-12 2014-02-27 Bayer Cropscience Nv Guard cell-specific expression of transgenes in cotton
MX343071B (es) 2011-09-13 2016-10-21 Monsanto Technology Llc Metodos y composiciones para el control de malezas.
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
CA2848689A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control targeting pds
WO2013040033A1 (en) 2011-09-13 2013-03-21 Monsanto Technology Llc Methods and compositions for weed control
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
ES2645927T3 (es) 2011-09-13 2017-12-11 Monsanto Technology Llc Procedimientos y composiciones para el control de malezas
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US9920326B1 (en) 2011-09-14 2018-03-20 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
US9826763B2 (en) * 2011-10-05 2017-11-28 Fmc Corporation Stabilizer composition of microcrystalline cellulose and carboxymethylcellulose, method for making, and uses
US9492363B1 (en) * 2012-01-16 2016-11-15 American Spraytech, L.L.C. Aerosol sprayable color composition
MX2014008693A (es) * 2012-01-27 2014-08-27 Agile Therapeutics Inc Administracion transdermica de hormonas.
FR2988566B1 (fr) * 2012-03-28 2014-08-08 Yoplait France Compositions alimentaires pour stimuler la formation de tissu osseux
UY34822A (es) 2012-05-24 2013-12-31 Seeds Ltd Ab Composiciones y métodos para silenciar la expresión genética
EP4215213A1 (en) * 2012-08-03 2023-07-26 MSM Innovations, Inc. Method and kit for bowel preparation
US9567631B2 (en) 2012-12-14 2017-02-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
CA2881685C (en) 2012-08-14 2023-12-05 10X Genomics, Inc. Microcapsule compositions and methods
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9617297B2 (en) * 2012-10-11 2017-04-11 The Regents Of The University Of California Apoplast wash fluid recovery for improved recombinant endoglucanase extraction in tabacco leaves
US10077451B2 (en) 2012-10-18 2018-09-18 Monsanto Technology Llc Methods and compositions for plant pest control
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9206436B2 (en) * 2012-12-20 2015-12-08 Ut-Battelle, Llc Key gene regulating cell wall biosynthesis and recalcitrance in Populus, gene Y
EP2941488B1 (en) 2013-01-01 2023-03-22 Monsanto Technology LLC Methods of introducing dsrna to plant seeds for modulating gene expression
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
US10000767B2 (en) 2013-01-28 2018-06-19 Monsanto Technology Llc Methods and compositions for plant pest control
CA2900543C (en) 2013-02-08 2023-01-31 10X Genomics, Inc. Partitioning and processing of analytes and other species
US8961680B2 (en) * 2013-03-08 2015-02-24 Tbf Environmental Technology Inc. Solvent formulations
WO2014165108A1 (en) * 2013-03-12 2014-10-09 Psivida Us, Inc. Bioerodible silicon-based delivery vehicles for delivery of therapeutic agents
CN105263329B (zh) 2013-03-13 2020-09-18 孟山都技术公司 用于杂草控制的方法和组合物
US10609930B2 (en) 2013-03-13 2020-04-07 Monsanto Technology Llc Methods and compositions for weed control
US20140283211A1 (en) 2013-03-14 2014-09-18 Monsanto Technology Llc Methods and Compositions for Plant Pest Control
US9289461B2 (en) * 2013-03-15 2016-03-22 Mead Johnson Nutrition Company Reducing the risk of autoimmune disease
US8889633B2 (en) 2013-03-15 2014-11-18 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof
US9345727B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional compositions containing a peptide component and uses thereof
CA2942000C (en) * 2013-03-15 2024-04-16 Maria Beug-Deeb Inc. Dba T&M Associates Methods and compositions for cleaning and disinfecting surfaces
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
US9345741B2 (en) 2013-03-15 2016-05-24 Mead Johnson Nutrition Company Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof
WO2014151381A1 (en) 2013-03-15 2014-09-25 Psivida Us, Inc. Bioerodible silicon-based compositions for delivery of therapeutic agents
US9352020B2 (en) 2013-03-15 2016-05-31 Mead Johnson Nutrition Company Reducing proinflammatory response
US9138455B2 (en) 2013-03-15 2015-09-22 Mead Johnson Nutrition Company Activating adiponectin by casein hydrolysate
CA2817728A1 (en) * 2013-05-31 2014-11-30 Pharmascience Inc. Abuse deterrent immediate release formulation
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
EP3608412A3 (en) 2013-07-19 2020-04-08 Monsanto Technology LLC Compositions and methods for controlling leptinotarsa
ES2693580T3 (es) * 2013-10-07 2018-12-12 Bristol-Myers Squibb Holdings Ireland Formulación de tratamiento del VIH de atazanavir y cobicistat
CA2929533C (en) 2013-11-04 2023-06-06 Monsanto Technology Llc Compositions and methods for controlling arthropod parasite and pest infestations
UA119253C2 (uk) 2013-12-10 2019-05-27 Біолоджикс, Інк. Спосіб боротьби із вірусом у кліща varroa та у бджіл
CN105979770B (zh) 2014-01-15 2019-07-05 孟山都技术公司 用于使用epsps多核苷酸的杂草控制的方法和组合物
ES2544153B1 (es) * 2014-02-24 2016-06-06 Ntd Labs, S.L. Uso de un hidrolizado de caseína como agente antiviral
US11091770B2 (en) 2014-04-01 2021-08-17 Monsanto Technology Llc Compositions and methods for controlling insect pests
CN106413896B (zh) 2014-04-10 2019-07-05 10X基因组学有限公司 用于封装和分割试剂的流体装置、系统和方法及其应用
WO2015200223A1 (en) 2014-06-23 2015-12-30 Monsanto Technology Llc Compositions and methods for regulating gene expression via rna interference
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
JP6838969B2 (ja) 2014-06-26 2021-03-03 １０エックス ジェノミクス， インコーポレイテッド 個々の細胞または細胞集団由来の核酸の分析方法
JP6640826B2 (ja) 2014-07-08 2020-02-05 ミメディクス グループ インコーポレイテッド 微粒子化ワルトン膠質
US20160022604A1 (en) * 2014-07-23 2016-01-28 Cadila Healthcare Limited Directly compressed ospemifene compositions
RU2754955C2 (ru) 2014-07-29 2021-09-08 Монсанто Текнолоджи Ллс Композиции и способы борьбы с насекомыми-вредителями
WO2016037745A1 (en) * 2014-09-11 2016-03-17 Gelita Ag Gelatin/pectin particles
CA2961639A1 (en) 2014-09-17 2016-03-24 Lonza, Inc. Activated disinfectant hydrogen peroxide compositions
US20160122817A1 (en) 2014-10-29 2016-05-05 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
US10471096B2 (en) * 2015-01-06 2019-11-12 Osamu Yamada Medicinal composition, blood treatment device, cosmetic, food and drink using combustion synthesis material
CN112126675B (zh) 2015-01-12 2022-09-09 10X基因组学有限公司 用于制备核酸测序文库的方法和系统以及用其制备的文库
MX2017009521A (es) 2015-01-22 2018-11-09 Monsanto Technology Llc Composiciones y métodos para controlar leptinotarsa.
EP4286516A3 (en) 2015-02-24 2024-03-06 10X Genomics, Inc. Partition processing methods and systems
KR20170119710A (ko) 2015-02-24 2017-10-27 10엑스 제노믹스, 인크. 표적화된 핵산 서열 커버리지 방법
WO2016137804A1 (en) 2015-02-25 2016-09-01 The Procter & Gamble Company Fibrous structures comprising a surface softening composition
US20160303043A1 (en) * 2015-04-16 2016-10-20 Kate Somerville Skincare, LLC Self-foaming compositions and methods
US10883103B2 (en) 2015-06-02 2021-01-05 Monsanto Technology Llc Compositions and methods for delivery of a polynucleotide into a plant
AU2016270913A1 (en) 2015-06-03 2018-01-04 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
JP6866343B2 (ja) 2015-07-10 2021-04-28 ザ プロクター アンド ギャンブル カンパニーＴｈｅ Ｐｒｏｃｔｅｒ ＆ Ｇａｍｂｌｅ Ｃｏｍｐａｎｙ メタセシス化不飽和ポリオールエステルを含む布地ケア組成物
SG11201804086VA (en) 2015-12-04 2018-06-28 10X Genomics Inc Methods and compositions for nucleic acid analysis
WO2017197338A1 (en) 2016-05-13 2017-11-16 10X Genomics, Inc. Microfluidic systems and methods of use
BR112019000371A2 (pt) 2016-07-08 2019-04-24 The Gillette Company Llc composições líquidas para dispositivos de remoção de pelos que compreendem ésteres de poliol insaturados metatetizados
DE102016223333A1 (de) * 2016-11-24 2018-05-24 Henkel Ag & Co. Kgaa Alkalische Mittel zum Aufhellen von Haaren enthaltend Oxidationsmittel und spezielle Carbonsäureester als Keratinvernetzer
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2018140966A1 (en) 2017-01-30 2018-08-02 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
MA47686A (fr) * 2017-03-01 2021-05-12 Arena Pharm Inc Compositions comprenant des agonistes du récepteur pgi2 et procédés de préparation associés
US10398670B2 (en) * 2017-04-24 2019-09-03 Knoze Jr. Corporation Oral microbiota promotion for oral and/or sinus infections
US10844372B2 (en) 2017-05-26 2020-11-24 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
EP4230746A3 (en) 2017-05-26 2023-11-01 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10471033B2 (en) * 2017-09-15 2019-11-12 Knoze Jr. Corporation Oral microbiota promotion for immune system associated inflammations
SG11201913654QA (en) 2017-11-15 2020-01-30 10X Genomics Inc Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
CN112262218A (zh) 2018-04-06 2021-01-22 10X基因组学有限公司 用于单细胞处理中的质量控制的系统和方法
AU2020348683A1 (en) * 2019-09-16 2022-04-28 Kiverdi, Inc. Microbial protein hydrolysate compositions and methods of making same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3764670A (en) * 1970-10-28 1973-10-09 Ministry Of Agriculture Polypeptidic anti-biotic substances derived from casein
US3778426A (en) * 1970-12-16 1973-12-11 Research Corp Therapeutically useful polypeptides
US4636384A (en) * 1982-06-03 1987-01-13 Stolle Research & Development Corporation Method for treating disorders of the vascular and pulmonary systems
US4959455A (en) * 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
JP2631470B2 (ja) * 1987-05-15 1997-07-16 雪印乳業株式会社 感染防御剤
US5344820A (en) * 1987-05-15 1994-09-06 Snow Brand Milk Products Co., Ltd. Infection protectant
JP2805490B2 (ja) * 1989-02-07 1998-09-30 雪印乳業株式会社 細菌毒素中和剤
US5514646A (en) * 1989-02-09 1996-05-07 Chance; Ronald E. Insulin analogs modified at position 29 of the B chain
FR2686085B1 (fr) * 1992-01-10 1995-08-04 Agronomique Inst Nat Rech Peptides representant des fragments du cmp, anticorps diriges contre lesdits peptides, et leurs utilisations.
GB9310472D0 (en) * 1993-05-20 1993-07-07 Univ Warwick Phenylalanine-free protein and dna coding thereof
TW282398B (xx) * 1993-12-22 1996-08-01 Bristol Myers Squibb Co
US5707968A (en) * 1994-05-26 1998-01-13 Abbott Laboratories Inhibition of attachment of H.influenzae to human cells
US5538952A (en) * 1994-05-26 1996-07-23 Abbott Laboratories Inhibition of infection of mammalian cells by respiratory syncytial virus
US5506209A (en) * 1994-05-26 1996-04-09 Abbott Laboratories Product for inhibition of infection of mammalian cells by respiratory syncytial virus
US5712250A (en) * 1994-09-16 1998-01-27 Abbott Laboratories Product for inhibition of human rotavirus infection
KR0140248B1 (ko) * 1995-03-23 1998-06-15 한상기 신규한 카제인 포스포펩티드, 그것을 포함하는 카제인 및 그 제조방법
US5985275A (en) * 1995-04-12 1999-11-16 New York Blood Center β-Lactoglobulin modified with aromatic anhydride compound for preventing HIV infection
US6570060B2 (en) * 1995-05-16 2003-05-27 Mclachlan Corran Norman Stuart Milk lacking β-casein A1
KR100221124B1 (ko) * 1996-09-23 1999-10-01 한상기 신규한 카제인 및 그 제조방법
US5830434A (en) * 1997-02-26 1998-11-03 Medical University Of South Carolina Foundation For Research Development Methods of treating non-insulin dependent diabetes mellitus with pancreatic polypeptide
EP0922769A4 (en) * 1997-03-21 2000-07-12 Snow Brand Milk Products Co Ltd HYDROLYSATE OF THE IRON-CASE COMPLEX AND A METHOD FOR ITS PRODUCTION.
US6358508B1 (en) * 1997-06-11 2002-03-19 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor TR9
PT996726E (pt) * 1997-08-29 2004-04-30 Brigham & Womens Hospital Proteina de membrana de celulas t (tirc7) peptidos e anticorpos dela derivados e suas utilizacoes
AUPP051497A0 (en) * 1997-11-24 1997-12-18 University Of Melbourne, The Antimicrobial peptides
US5985575A (en) * 1998-05-20 1999-11-16 Wisconsin Alumni Research Foundation Tethered function assay for protein function
US6570606B1 (en) * 1998-05-29 2003-05-27 3Com Corporation Method and apparatus for controlling transmission of media signals over a data network in response to triggering events at participating stations
WO2000029008A2 (en) * 1998-11-16 2000-05-25 Board Of Regents, The University Of Texas System Hiv-specific t-cell induction
GB9927603D0 (en) * 1999-11-22 2000-01-19 Nestle Sa Use of a milk protein hydrolysate in the treatment of diabetes
IL138946A0 (en) * 2000-10-11 2001-11-25 Compugen Ltd Method for the identification of peptides and proteins
US20080293671A1 (en) * 2005-09-28 2008-11-27 Dnp Canada, Inc. Combination of Polychitosamine and Fibrate for the Prevention and Treatment of Hyperlipidemia
US8865876B2 (en) * 2008-06-02 2014-10-21 California Institute Of Technology Engineered lectin oligomers with antiviral activity

Also Published As

Publication number Publication date
AU782662B2 (en) 2005-08-18
JP2003528827A (ja) 2003-09-30
NO20024157L (no) 2002-10-30
EA007814B1 (ru) 2007-02-27
EA007217B1 (ru) 2006-08-25
US20090192081A1 (en) 2009-07-30
EP1261360B1 (en) 2009-12-16
US20100317601A1 (en) 2010-12-16
US20020147144A1 (en) 2002-10-10
US20070161557A1 (en) 2007-07-12
CN1427725A (zh) 2003-07-02
EA200401467A1 (ru) 2005-04-28
US7741274B2 (en) 2010-06-22
HUP0301003A3 (en) 2007-08-28
DE60140794D1 (de) 2010-01-28
EA005579B1 (ru) 2005-04-28
EP1261360A1 (en) 2002-12-04
KR20030025907A (ko) 2003-03-29
CA2401550A1 (en) 2001-09-07
US8735348B2 (en) 2014-05-27
HUP0301003A2 (hu) 2003-07-28
EP1261360A4 (en) 2004-03-10
BR0109027A (pt) 2003-06-03
AU3596201A (en) 2001-09-12
NZ521016A (en) 2005-08-26
ATE451929T1 (de) 2010-01-15
NO20024157D0 (no) 2002-08-30
IL151351A (en) 2012-04-30
CZ20022915A3 (cs) 2003-03-12
PL361307A1 (en) 2004-10-04
WO2001064234A1 (en) 2001-09-07
ZA200206842B (en) 2003-07-28
EA200400376A1 (ru) 2005-06-30
MXPA02008569A (es) 2003-02-24
US20130096073A1 (en) 2013-04-18
US20100298216A1 (en) 2010-11-25
EA200200820A1 (ru) 2003-08-28
DK1261360T3 (da) 2010-05-03

Similar Documents

Publication Publication Date Title
IL134830A0 (en) Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
WO2005081628A3 (en) Casein derived peptides and therapeutic uses thereof
AU3698697A (en) Method for preserving infectious recombinant viruses, aqueous viral suspension and use as medicament
ATE242633T1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
DE69838986D1 (de) Polypeptide, deren herstellung und verwendung
MXPA03001673A (es) Bacteria de acido lactico capaz de reducir una tendencia individual a desarrollar reacciones alergicas.
WO2000054813A3 (en) Use of recombinant gene delivery vectors for treating or preventing diseases of the eye
KR20040078639A (ko) 카세인 유도 펩타이드 및 이들의 치료 용도
DK1095061T3 (da) Peptider baseret på sekvensen af humant lactoferring og deres anvendelse
ZA87141B (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors,biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
WO2001034641A8 (en) Antimicrobial activity of the first cationic cluster of human lactoferrin
NZ505834A (en) Compositions containing polypeptides isolated from mycobacterium vaccae and methods for their use
WO2000030667A3 (en) Compositions and methods using lactadherin or variants thereof
FR2870126A1 (fr) Vecteur lentiviral recombinant d'expression d'une proteine de flaviviridae et ses applications comme vaccin
WO2000006735A8 (en) Interferon alpha hybrids
WO2000077177A3 (en) Isolation of a human retrovirus
CA2163805A1 (en) Novel activating factor of leukocytes
WO1997040073A3 (de) BIOLOGISCH AKTIVER EIWEISSSTOFF - KOLLAGENFRAGMENT HF-COLL-18/514cf - ZUR HEMMUNG DES WACHSTUMS VON TUMOREN UND VON GEFÄSSWUCHERUNGEN
NZ514027A (en) Cloning and expression of haemophilus somnus transferrin-binding proteins
MD2053B1 (en) Remedy with interferon inducing action
DK1250422T3 (da) Myeloid-kolonistimulerende faktor og anvendelser deraf
WO2000029433A3 (en) 12-25-kda bacterial proteins and their 116-58 kda polymers for use e.g. in anti-tumor vaccines
HK1123813A1 (en) Anti-tumor drug, medicament, composition, and use thereof
NZ509773A (en) Casein formulations for the delivery of bioactive constituents